SCHEMBL379790

SCHEMBL379790

Fc1ccc(-c2csc3ccnc(NCc4ccco4)c23)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.52
MAPT P10636 6/20 0.52
ALDH1A1 P00352 5/20 0.52
KCNH3 Q9ULD8 2/20 0.43
MAPK14 Q16539 1/20 0.42
MAPK1 P28482 4/20 0.42
KMT2A Q03164 4/20 0.42
MEN1 O00255 3/20 0.42
ESR1 P03372 1/20 0.42
POLB P06746 1/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ESR2 Q92731 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
LMNA P02545 2/20 0.41
HTT P42858 1/20 0.41
XBP1 P17861 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL379745 0.90 EED (0.49) KDM4EMAPTALDH1A1MAPK1KMT2A
SCHEMBL379640 0.89 MAPT (0.53) KDM4EMAPTALDH1A1MAPK1KMT2A
SCHEMBL3385444 0.83 ALDH1A1 (0.66) KDM4EMAPTALDH1A1MAPK1KMT2A
SCHEMBL380531 0.83 UTS2R (0.47) KDM4EMAPTALDH1A1KCNH3MAPK14
SCHEMBL379602 0.83 PDE11A (0.47) KDM4EMAPTALDH1A1MAPK14MAPK1
SCHEMBL4946829 0.82 PDE11A (0.49) KDM4EMAPTALDH1A1MAPK14MAPK1
SCHEMBL379685 0.80 SMN1; SMN2 (0.47) KDM4EMAPTALDH1A1MAPK1KMT2A
SCHEMBL380352 0.79 HSD17B10 (0.48) KDM4EMAPTALDH1A1MAPK1KMT2A
SCHEMBL379868 0.75 TUBB4A (0.45) KDM4EMAPTALDH1A1SMN1; SMN2LMNA
SCHEMBL379865 0.73 ESR1 (0.55) KDM4EALDH1A1MAPK1ESR1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1968982-B1 THIENO (3,2-C) PYRIDINE COMPOUNDS XENTION LTD (GB) 2012-01-25 EP claimed
EP-1968982-A2 THIENO (3,2-C) PYRIDINE COMPOUNDS Xention Discovery Ltd. (GB) 2008-09-17 EP claimed
US-20070161672-A1 Compounds XENTION LIMITED 2007-07-12 US claimed
WO-2007066127-A2 THIENO ( 3 , 2-C) PYRIDINE COMPOUNDS XENTION LIMITED (GB) 2007-06-14 WO claimed
US-9216992-B2 Thieno[3,2-c]pyridine potassium channel inhibitors XENTION LIMITED (GB) 2015-12-22 US disclosed
EP-1968982-B1 THIENO (3,2-C) PYRIDINE COMPOUNDS XENTION LTD (GB) 2012-01-25 EP disclosed
EP-1968982-A2 THIENO (3,2-C) PYRIDINE COMPOUNDS Xention Discovery Ltd. (GB) 2008-09-17 EP disclosed
US-20070161672-A1 Compounds XENTION LIMITED 2007-07-12 US disclosed
WO-2007066127-A2 THIENO ( 3 , 2-C) PYRIDINE COMPOUNDS XENTION LIMITED (GB) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161672-A1 Compounds KCNJ2, KCNT1, KCNT2 KDM4E 1216/4885MAPT 3501/4885ALDH1A1 371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.